Oncternal Therapeutics, Inc. financial data

Symbol
ONCT on Nasdaq
Industry
Pharmaceutical Preparations
Location
12230 El Camino Real, Suite 230, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
GTX INC /DE/ (to 6/11/2019), GTX INC/TN (to 1/15/2004)
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 400 % -57.5%
Debt-to-equity 35.3 %
Return On Equity -178 % -108%
Return On Assets -131 % -73.8%
Operating Margin -1.66K % +75.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.96M shares -95%
Common Stock, Shares, Outstanding 2.96M shares -95%
Entity Public Float 18.8M USD -64.3%
Common Stock, Value, Issued 3K USD -94.9%
Weighted Average Number of Shares Outstanding, Basic 2.96M shares +0.41%
Weighted Average Number of Shares Outstanding, Diluted 2.96M shares +0.41%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.16M USD +228%
General and Administrative Expense 12.3M USD -3.45%
Operating Income (Loss) -36M USD +18.3%
Net Income (Loss) Attributable to Parent -34.6M USD +17.1%
Earnings Per Share, Basic -11.7 USD/shares +55.9%
Earnings Per Share, Diluted -11.7 USD/shares +55.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13.1M USD -12.4%
Assets, Current 15.4M USD -63.6%
Operating Lease, Right-of-Use Asset 154K USD -47.1%
Other Assets, Noncurrent 0 USD -100%
Assets 15.6M USD -63.9%
Accounts Payable, Current 1.2M USD -43.8%
Employee-related Liabilities, Current 592K USD -52.2%
Accrued Liabilities, Current 5.06M USD +76.6%
Liabilities, Current 6.45M USD +25.3%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 6.45M USD +4.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1K USD
Retained Earnings (Accumulated Deficit) -223M USD -18.3%
Stockholders' Equity Attributable to Parent 9.15M USD -75.3%
Liabilities and Equity 15.6M USD -63.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.44M USD +32.2%
Net Cash Provided by (Used in) Financing Activities -87K USD -108%
Net Cash Provided by (Used in) Investing Activities 7.22M USD
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 2.96M shares -95%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -301K USD +98.8%
Deferred Tax Assets, Valuation Allowance 66.6M USD +15%
Operating Lease, Liability 191K USD -44.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -34.6M USD +17.1%
Lessee, Operating Lease, Liability, to be Paid 200K USD -47.1%
Operating Lease, Liability, Current 191K USD +26.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 150K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 50K USD -74.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9K USD -75%
Deferred Tax Assets, Operating Loss Carryforwards 30M USD +7.56%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 232M USD +3.01%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 66.6M USD +15%
Share-based Payment Arrangement, Expense 6.81M USD -3.81%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%